Subscribe
Subscribe

Finance and Investment, Industrial application, Technology and digital innovation

flanders.healthTech launches 14 unique innovation projects in healthcare

Ghent, Belgium, 10 March 2022 – Following the launch of the cluster flanders.healthTech in 2021, the first round of 14 consortia have started working on innovation projects in healthcare. The projects have received a total of EUR 4.7 million in VLAIO support from Flemish Minister of Economy and Innovation Hilde Crevits to help make a difference in the field of technology and innovation in healthcare.

V-Bio Ventures’ Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio

miDiagnostics ultra-fast COVID-19 PCR Test succeeds in Brussels Airport pilot study

Leuven, Belgium, 17 February 2022 - miDiagnostics, a fast-growing POC diagnostics company backed by Belgian Family Offices, announces the success of the Brussels Airport pilot study for its ultra-fast COVID-19 PCR Test. This test is the first of many applications for miDiagnostics’ disruptive technology, licensed from imec (Leuven, Belgium) and developed in close collaboration with Johns Hopkins University. The study confirms that the test can perform rapid and high-quality diagnostics on the spot in a real-life setting, providing travelers with a result within half an hour with the same accuracy as a traditional PCR test.

SciMingo SciComm Academy launches spring program of workshops and lectures

Imitating nature: H2WIN’s innovative solution enables production of green hydrogen

Belgian GreenTech company H2WIN has developed H2GREEN: an ingenious system to make hydrogen production 100% renewable, more efficient, less expensive, and less energy consuming. Based in Nivelles, H2WIN drew inspiration from nature’s own ancient methods of generating energy: photosynthesis. The company is currently looking for funding to finance the next steps towards industrial-scale production.

Ann Van Gysel appointed CEO of flanders.healthTech

Ghent, Belgium, 20 January 2022 – Dr. Ann Van Gysel has been appointed as CEO of the flanders.healthTech spearhead cluster. She will lead the cluster, which brings together personalized and digital medicine and healthcare technology in Flanders, and supports the development and implementation of new technologies in the Flemish healthcare sector.

ElmediX raises nearly 12 million euros to develop innovative heat technology to fight cancer

Mechelen, Belgium, January 25, 2022 - Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of cancer. A new capital injection of 4M euros brings the total to almost 12M euros (including VLAIO research grants worth 1.8M euros) and accelerates the trajectory of this innovative MedTech company.

Belgium: The Health & Biotech Valley of Today and Tomorrow

As part of the ‘Health & Biotech Valley of Tomorrow’ initiative, the Belgian government recently signed a charter together with stakeholders from academia and industry, pledging to cement Belgium’s status as a biotech powerhouse in the next 10 to 20 years. Over the next few months, working groups will translate recommendations of a consultancy report into a concrete strategic plan for the future of the country. Amongst other topics, experts will evaluate ways to encourage more collaboration, provide financial stimuli, and make better use of health data.

Long COVID: what it means for the life sciences industry and other chronic conditions

Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.

Saving kidneys with a test that improves early detection of transplant rejection

Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.

V-Bio Ventures participates in the EUR 12 million seed round of heart failure biotech Corteria Pharmaceuticals

Ghent, Belgium, 9 December 2021 – Corteria Pharmaceuticals, a French biotechnology company specialized in the development of interceptive therapies for heart failure subpopulations, today announced the successful completion of its Seed round, providing EUR 12 million to pursue the development of a series of programs in-licensed from Sanofi S.A. (Paris, France). The seed round was led by Kurma Partners and includes V-Bio Ventures, Omnes Capital, and InVivo Capital. As part of the financing, Thierry Laugel (Chair) and Peter Neubeck from Kurma Partners, Ward Capoen from V-Bio Ventures, Claire Poulard from Omnes Capital, and Luis Pareras from InVivo Capital Health will join the Board of Directors.

Unlocking doors: Key considerations for start-ups during Discovery and Development

Mark Hicken is Vice President of Strategy for Europe, Middle East and Africa (EMEA) at the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). With more than 20 years of experience in the company, Mark leads a cross-functional team that drives Janssen’s continued growth across the region, in close collaboration with the local operating companies. On the 28th of October, Mark presented a talk during an online event hosted by Johnson & Johnson Innovation – JLABS (JLABS) ‘Start at the End: Thinking Commercial during Discovery and Development’ (recording available here). Following the webinar, Mark shared some additional insights and advice with us.

New start-up Trince raises EUR 4 million for innovative technology to produce personalized cancer therapies safer, cheaper, and faster

Rejuvenate Biomed: Expanding peoples’ health spans by boosting cell resilience

Aging will affect each and every one of us at some point; it is part of the covenant of life. However, just as we have learned to treat and prevent various forms of cancers and cardiovascular diseases, there are numerous ways which we can improve peoples’ health spans. Rejuvenate Biomed is a young Belgian company in this field, leveraging safe prescription drugs to improve cell resilience and help us stay well for longer.

Confo-dently into the future!

Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, launched in 2015 as a spin-off of the Vrije Universiteit Brussel (VUB) and VIB, is now taking the big step from the preclinical to the clinical stage with a GPCR drug for neuropathic pain.